Article | Open | Published:

Restoration of GLP-1 secretion by Berberine is associated with protection of colon enterocytes from mitochondrial overheating in diet-induced obese mice

Nutrition & Diabetesvolume 8, Article number: 53 (2018) | Download Citation

Abstract

Objective

L-cell dysfunction is reported for GLP-1 reduction in type 2 diabetes. However, the mechanism of dysfunction remains unknown. In this study, we examined mitochondrial function in the mechanistic study in diet-induced obese (DIO) mice.

Subjects

C57BL/6 mice were fed a high-fat diet (HFD) for 16 weeks to establish the DIO model for GLP-1 reduction. The mice were then treated with berberine (BBR) (100 mg/kg/day) for 8 weeks to test the impact on GLP-1 expression. Mitochondrial activities of the colon enterocytes were compared among three groups of mice (lean, DIO, and DIO + BBR) at the end of treatment. Gut microbiota and short-chain fatty acids (SCFAs) were examined to understand the mitochondrial responses. A cellular model treated with palmitic acid (PA) was used in the mechanism study.

Results

A reduction in GLP-1 expression was observed in DIO mice with mitochondrial stress responses in the colon enterocytes. The mitochondria exhibited cristae loss, membrane rupture, and mitochondrial swelling, which was observed with an increase in ATP abundance, complex I activity, and deficiency in the activities of complexes II and IV. Those changes were associated with dysbiosis and a reduction in SCFAs in the colon of DIO mice. In the cellular model, an increase in ATP abundance, loss of mitochondrial potential, and elevation of apoptosis were induced by PA. All of the alterations in DIO mice and the cellular model were attenuated by BBR.

Conclusion

The mitochondrial stress responses were observed in the colon enterocytes of DIO mice for GLP-1 reduction. The stress was prevented by BBR in the restoration of GLP-1 expression, in which BBR may act through direct and indirect mechanisms.

Introduction

GLP-1 (glucagon-like peptide 1) is a gut hormone, which is a valid target in the control of blood glucose in the treatment of type 2 diabetes. A reduction in plasma GLP-1 contributes to the disorder of blood glucose1. Restoration of plasma GLP-1 is a successful strategy in the control of hyperglycemia in the type 2 diabetes patients. Blood GLP-1 is determined by the secretion function of L-cells in the intestine and clearance function in many tissues through DPP-4 (dipeptidyl-peptidase 4)-mediated protein degradation. Inhibition of the clearance process using DPP-4 inhibitors (such as Sitagliptin) is a successful strategy in the induction of plasma GLP-1 in clinics. However, induction of GLP-1 secretion has not been successful in the clinical setting2. L-cell dysfunction, not L-cell number reduction, is a mechanism for the decline of plasma GLP-13,4,5. However, the role of mitochondria in L-cell dysfunction remains unknown. We addressed this issue by studying mitochondria in the colon enterocyte of diet-induced obese (DIO) mice.

Berberine (BBR) is widely used in the treatment of type 2 diabetes in Asian countries6. However, the mechanisms remain to be established for the metabolic effects of BBR. Our early studies suggest that BBR downregulates ATP production in mitochondria for activation of AMPK7. BBR inhibits the mitochondrial respiration in the inhibition of ATP production, which leads to the elevation of the AMP/ATP ratio7,8,9. BBR was reported to enhance GLP-1 expression in the intestine10,11. However, the impact of BBR on mitochondria remains unknown in the GLP-1 regulation. We examined mitochondrial response to BBR in the colon of DIO mice to address this issue.

In this project, we investigated the role of mitochondria in the mechanism of L-cell dysfunction in the colon mucosa. The L-cell dysfunction was found with mitochondrial stress responses in the DIO mice. BBR is able to inhibit the stress responses to preserve the L-cell function.

Materials and methods

Chemicals and reagents

Berberine (BBR) was obtained from the National Institute for Food and Drug Control (Beijing, China). The standard chemicals included acetic acid, propionic acid, butyric acid, isobutyric acid, pentanoic acid, isovaleric acid, and 2-methyl valerate. All of the chemicals was more than 98% in purity. Other chemicals included adenosine 5′-diphosphate sodium salt (ADP), fatty acid-free bovine serum albumin (BSA), carbonyl cyanide 4-(trifluoromethoxy) phenylhydrazone (FCCP), oligomycin, antimycin A, rotenone, and succinic acid. Mitochondrial isolation buffer (MSHE + BSA) contains 210 mM mannitol, 70 mM sucrose, 1 mM EGTA, 5 mM HEPES, and 0.5% (w/v) fatty acid-free BSA (pH 7.2). Mitochondrial assay solution (MAS, 1×) contains 220 mM mannitol, 70 mM sucrose, 5 mM MgCl2, 10 mM KH2PO4, 2 mM HEPES, 1 mM EGTA, and 0.2% (w/v) fatty acid-free BSA, pH 7.2 at 37 °C. A 2–3× stock of MAS was prepared for dilution of substrates, ADP, and respiration reagents. Stock solution of succinate (0.5 M) and ADP (1 M) were made in H2O and pH 7.2 was adjusted with potassium hydroxide. Stocks of 10 mM FCCP, 2 mM rotenone, 5 mg/ml oligomycin, and 40 mM antimycin A were made in 95% ethanol. All of the chemicals were purchased from Sigma-Aldrich Co. Ltd. (Shanghai, China) unless stated separately. All of the reagents were stored at −20 °C except pyruvate, which was prepared fresh on the day of experiment.


Animals

The animal experiments were conducted in accordance with the protocol approved by the Institutional Animal Care and Use Committee (IACUC) of Shanghai Jiao Tong University. Male C57BL/6J mice (SPF grade) at 8 weeks in age were obtained from the Shanghai Slac Laboratory Animal Co. Ltd (Shanghai, China). The mice were kept in the animal facility with controlled temperature (20 ± 2 °C), humidity (60 ± 5%), and light cycle at 12 h dark/light. Normal control mice were fed a regular chow diet (NCD, 13.5% calorie in fat; Shanghai Slac Laboratory Animal Co. Ltd). DIO mice (20 mice) were generated by feeding a high-fat diet (HFD, 60% calorie in fat; Research diets, # D12492) for 16 weeks as described elsewhere12. DIO mice were divided randomly into two groups: HFD control group (10 mice) and BBR-treated HFD group (10 mice). BBR was delivered through dietary supplementation at 100 mg/kg/day. The mice were treated for 8 weeks with BBR, in which the mice were minored for body weight, food intake, and water intake. Fresh stool samples were collected at 0, 4, and 8 weeks of the treatment and stored at −80 °C immediately for subsequent analysis.

At the end of treatment, mice were subject to tissue collection under anesthesia with intraperitoneal injection of pentobarbital (35 mg/kg). Orbital bleeding was applied in the blood collection. Serum was isolated by centrifugation at 3000 g at 4 °C for 10 min and stored at −80 °C until the biochemical assays. The mice were sacrificed by cervical dislocation after blood collection. Livers, colons, and visceral fat tissues were collected and immediately weighed. The tissue samples were rinsed in phosphate-buffered saline (pH 7.4), frozen in liquid nitrogen immediately, and stored at −80 °C until subsequent analysis.


Histological analysis

The colon tissue samples were fixed in 10% phosphate-buffered formalin acetate at 4 °C overnight and embedded in paraffin wax. Paraffin sections (5 μm) were made and mounted on the glass slides for hematoxylin and eosin (H&E) staining13. The paraffin sections of colons were stained by Alcian blue-periodic acid-schiff (AB-PAS) staining according to the manufacturer’s instructions (Solarbio, Beijing, China).


Glucose tolerance test and blood lipids

Glucose tolerance test (GTT) was performed in the mice after 16 h fasting with peritoneal injection of glucose (2 g/kg). Blood glucose was tested in the tail vein blood at 0, 15, 30, 60, and 120 min using a One Touch glucometer (ACCU-CHEK® performa, Roche). The insulin sensitivity index HOMA-IR [=fasting insulin (mU/l) × fasting glucose (mmol/l)/22.5] was calculated according to the fasting insulin and glucose concentration7. Blood lipid profile was examined for serum triglyceride, total cholesterol, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol using an autoanalyzer (Hitachi 7600-020, automatic analyzer).


Insulin and GLP-1 assays

Fasting insulin was determined in serum of mice fasted for 6 h with an ELISA kit (Thermo Fisher Scientific, Waltham, MA, USA). GLP-1 was determined in the plasma with the GLP-1 Platinum ELISA kit (BMS2194; eBioscience, California, USA). Blood (300 μl) was collected in tube containing EDTA and DPP-IV inhibitor (1 mM). The plasma was collected after centrifugation at 3000 g for 10 min at 4 °C and stored at −80 °C until test. Insulin and GLP-1 data were analyzed with the DENLEY DRAGON Wellscan MK 3 software (Thermo, with Ascent software for Multiskan).


Microflora assay

Gut microflora was tested using the fecal samples with the 16s ribosomal RNA protocol14. The bacterial genomic DNA was prepared and stored at −20 °C prior to the sequence analysis.

Amplification of the bacterial 16s rRNA genes V3–V4 region was performed using the forward primer 338F (5′-ACTCCTACGGGAGGCAGCA-3′) and the reverse primer 806R (5′-GGACTACHVGGGTWTCTAAT-3′) in PCR. PCR products were purified with Agencourt AMPure Beads (Beckman Coulter, Indianapolis, IN) and quantified using the PicoGreen dsDNA Assay Kit (Invitrogen, Carlsbad, CA, USA). After the individual quantification step, amplicons were pooled in equal amounts, and pair-end 2×300 bp sequencing was performed using the Illlumina MiSeq platform with MiSeq Reagent Kit v3 at Shanghai Personal Biotechnology Co., Ltd (Shanghai, China). The Quantitative Insights Into Microbial Ecology (QIIME, v1.8.0) pipeline was employed to process the sequencing data in microbiota analysis. Taxonomical assignments of representative sequences were determined using the RDP classifier with a bootstrap cutoff of 50%.


Fatty acid assay

The fatty acids were isolated from the frozen fecal samples (0.1 g) and tested using gas chromatography. In assay of short-chain fatty acids (SCFAs), the fecal samples were reconstituted in 0.4 ml distilled water and the supernatant was acidified with a 1/5 volume of 50% H2SO4 and 1/2 volume of dilution internal standard solution (50 μg/ml), and then extracted with organic solvent ethyl ether. The concentrations of acetic acid, propionic acid, isobutyric acid, butyric acid, valeric acid, and isovaleric acid were determined in the organic phase using gas chromatography (GC-2010; Shimadzu Cooperation, Kyoto, Japan) with a flame ionization detector and an Alltech capillary column (AT-WAX, 30 m × 0.25 mm × 0.25 μm; Alltech Company, ME, USA) operated in the split-less mode. The helium carrier flow was 37.0 cm/s under a column head pressure of 68.0 kPa. The oven temperature was initially 100 °C for 1 min, increased to 170 °C at a rate of 5 °C/min, gradually increased to 230 °C at a rate of 30 °C/min, and maintained for 2 min. The injector and detector temperatures were set at 220 and 250 °C, respectively.

In assay of long-chain fatty acids (LCFAs), the fecal samples were acidified with 1.0 ml 5% H2SO4 and 100 μg of dilution internal standard solution (19:0 methyl ester, 10 μl from 10 mg/ml), and then was grinded at 60 Hz for 3 min. The homogenate solution was heated at 80 °C  for 90 min. LCFAs were extracted from cooling homogenate with 1.5 ml 0.9% NaCl and 200 μl Hexane. The concentrations of LCFAs were determined in the organic phase using gas chromatography equipped with a flame ionization detector and an DB-5MS column (30 m × 0.25 mm × 0.25 μm; Agilent, USA). The oven temperature was initially 70 °C for 5 min, increased to 200 °C at a rate of 25 °C/min and 240 °C at a rate of 2 °C/min, gradually increased to 300 °C at a rate of 20 °C/min, and maintained for 10 min. The injector and detector temperatures were set at 270 and 320 °C, respectively.


Quantative real-time PCR (qRT-PCR)

Total RNA was extracted from the frozen tissues using the TRIzol RNA isolation reagent (Invitrogen, Carlsbad, CA). Reverse transcription was carried out in 500 ng RNA using the Prime ScriptTM 1st Strand cDNA Synthesis Kit (TaKaRa, Japan). The qRT-PCR reaction was performed in 20 μl (SYBR Premix Ex TaqTM; TaKaRa Japan) using the applied primer sequences listed in the Supplementary Table 1. The result was normalized against GAPDH mRNA signal.


Mitochondria and ATP assay

Mitochondria were isolated from the colon tissue by differential centrifugation, and mitochondrial oxygen consumption rates (OCR) were measured in 5 μg using an XF24 Analyzer (Seahorse Bioscience Inc., North Billerica, MA)15. For coupling assay, OCR was measured with succinate/rotenone (10 mM/2 μM) in the presence of ADP (4 mM, state 3), oligomycin (2.5 μg/ml, for state 4o), carbonyl cyanide 4-(trifluoromethoxy) phenylhydrazone (FCCP, 4 μM, for state 3u), and antimycin A (4 μM, for nonspecific respiratory background signal). The respiration control rate (RCR) was calculated by state 3/state 4o for the mitochondrial function. The mitochondrial complex assay was performed with 5 μg mitochondria per well, 10 mM pyruvate, 2 mM malate, and 4 mM FCCP. Others  included rotenone (2 mM), succinate (10 mM), antimycin A (4 mM final), and ascorbate plus 1 mM N,N,N9,N9-tetramethyl-p-phenylenediamine (TMPD, 10 and 100 mM, respectively). ATP level was determined in the fresh tissues with the EnzyLightTM ATP Assay Kit (EATP-100; BioAssay Systems, Northern California, USA).


Ultrastructure of mitochondria

The fresh colon tissues were rapidly sliced on ice and fixed in 4% glutaraldehyde solution. Specimen of electron microscope was fixed in 1% osmium acid, dehydrated with gradient ethanol, embedded in epoxy resin, and sectioned in ultrathin. The mitochondrial ultrastructure was observed with a transmission electron microscopy (Tecnai G2 Spirit Biotwin/*Tecnai G2 spirit Biotwin, 120kv) .


Mitochondrial stress responses in cellular model

NCI-H716 cells (CCL-251™; ATCC) were purchased from ATCC, and cultured in 1640 medium with 10% fetal bovine serum without mycoplasma contamination. In the cellular assay, the cells were maintained in Dulbecco's modified Eagleʼs medium supplemented with 0.2% BSA. Mitochondrial stress responses and cell apoptosis were induced by treatment of the cells with palmitic acid (Palmitate) for 24 h at a final concentration of 500 µM. BBR was used at a final concentration of 100 µM to inhibit the cell responses. ATP was determined in the cell lysate using the kit described above. Mitochondrial potential was determined with JC-1 fluorescent dye (Beyotime, Shanghai, China) in combination with the flow cytometry. OCR was determined with the Seahorse technology. Apoptosis was determined with an Annexin V-FITC Apoptosis Detection Kit (Dojindo, Shanghai, China) and cell necrosis was determined with propidium iodide (PI) staining using the flow cytometry.


Data analysis

The statistical analysis was conducted by excluding the highest and lowest values in the data available in each group to ensure variance similar between groups. The statistical analyses were performed using two-way ANOVA and Student’s t-test. Results were expressed as the mean ± SEM. P-value < 0.05 was considered statistically significant.

Results

Inhibition of obesity and hyperlipidemia by BBR

DIO mice were generated in C57BL/6 mice with 16 weeks of HFD feeding. BBR was delivered to DIO mice through dietary supplementation for 8 weeks to establish the metabolic impact in the DIO model. The impact included inhibition of weight gain in DIO mice (Fig. 1a), which was observed as early as 4 weeks of treatment without suppression of calorie intake (Fig. 1b). The inhibition was associated with a less gain in fat mass (epididymal and perirenal fat) (Fig. 1c). The impact of BBR was also observed with a reduction in hyperlipidemia with parameters including the low-density lipoprotein C, total cholesterol, and total triglyceride (Fig. 1d). High-density lipoprotein C was increased by the BBR treatment (Fig. 1d). The data suggest that the metabolic activities of BBR were established in the DIO mice.

Fig. 1
Fig. 1

Inhibition of obesity and hyperlipidemia by BBR. a Body weight at 0, 4, and 8 weeks of treatment. b Average daily calorie intake per mouse. c Tissue weight of perirenal fat and epididymal fat pads after 8 weeks of treatment. d Serum lipid levels after 8 weeks of treatment. The BBR treatment was administrated for 8 weeks in DIO mice after 16 weeks on high-fat diet. Data are presented as the mean ± SEM (n = 6). *P < 0.05 HFD versus NCD, #P < 0.05 HFD + BBR versus HFD

Improvement of glucose metabolism by BBR

To test the BBR activity further, glucose metabolism was examined in the mice at the 4 and 8 weeks of the treatment. An improvement in fasting glucose and fasting insulin was observed (Fig. 2a, b), which led to a favorite change of insulin sensitivity index of HOMA-IR (Fig. 2c). The improvement was extended in GTT at 4 and 8 weeks (Fig. 2d–f). Insulin signaling activities was enhanced in the liver as indicated by the reduced expression of the gluconeogenic genes (G6Pase and PEPCK) (Fig. 2g, h). This group of data suggests that the glucose metabolism was improved by BBR in the DIO mice.

Fig. 2
Fig. 2

Improvement of insulin sensitivity by BBR. a Fasting blood glucose. b Fasting serum insulin. c HOMA-IR. d GTT at 4 weeks of BBR treatment. GTT was performed by intraperitoneal injection of glucose (2 g/kg body weight). e GTT at 8 weeks of BBR treatment. f Area under the curve of GTT assays. g mRNA of G6Pase in liver tissue at 8 weeks of BBR treatment. h mRNA of PEPCK in liver tissue at 8 weeks of BBR treatment. Data are presented as the mean ± SEM (n = 6). *P < 0.05 HFD versus NCD, #P < 0.05 HFD + BBR versus HFD

Regulation of L-cells by BBR

L-cells are located in the epithelial layer of the intestine mucosa and responsible for secretion of the gut hormone GLP-1. A reduction in the serum GLP-1 was observed in DIO mice (Fig. 3a), which was associated with a dramatic decrease in GLP-1 mRNA in the colon tissue (Fig. 3b). These alterations were all corrected in DIO mice treated by BBR (Fig. 3a, b). GPR43 is a receptor of SCFAs in the L-cells, and involved in induction of GLP-1 expression by SCFAs16. GPR43 expression was decreased by 80% in DIO mice, and the reduction was also corrected by BBR (Fig. 3c). This group of data suggests that BBR may preserve GLP-1 expression through an impact on L-cells in the colon.

Fig. 3
Fig. 3

Upregulation of GLP-1 and GPR43 in colon by BBR. a Plasma GLP-1. b mRNA expression of GCG in colon tissues. c mRNA expression of GPR43 in the mouse colon tissues. Data are presented as the mean ± SEM (n = 6). *P < 0.05 HFD versus NCD, #P < 0.05 HFD + BBR versus HFD

Mitochondrial damage in colon enterocytes of DIO mice

Colon histology and enterocyte mitochondria structure were examined to understand the L-cell dysfunction. The colon tissue integrity and mucus content were examined in the tissue slide under a microscope with H&E staining and AB-PAS staining. Three major histological changes were observed in the DIO mice: loss of mucosa content, loss of epithelial layer in the mucosa surface, and un-even thickness of the mucosal layer (Fig. 4a). Those morphological changes were all improved in DIO mice by BBR.

Fig. 4
Fig. 4

Restoration of mucosal and mitochondrial structure in colon by BBR. a Colon tissue histology. Representative fields of H&E staining and AB-PAS staining were taken from the colon tissue slides (×100, scale bars, 100 μm). In HFD mice, the mucosa was damaged and the mucous content was decreased with epithelial cell detached, and these changes were improved by BBR. b Mitochondrial structure under the transmission electron microscope. The image was taken at 98,000 times of magnitude

To understand the mechanism of morphological changes, mitochondria super structure was examined in the enterocytes using the transmission electron microscope. Mitochondria exhibited a structural damage for a loss of cristae and an increase in membrane rupture (Fig. 4b). These changes were associated with a size increase in mitochondria (Fig. 4b), a sign of swelling. The structural changes were corrected in the DIO mice treated by BBR. The structural damage suggests a mechanism for the morphological changes in mitochondria of the colon tissue of DIO mice. Inhibition of the damage by BBR suggests a new activity of BBR in the regulation of enterocyte function.

Mitochondrial dysfunction in enterocytes

Mitochondrial function was examined in the colon tissue in the study of L-cell function. Tissue ATP abundance and mitochondrial oxygen consumption were examined in the colon tissue. The ATP abundance was elevated in the homogenization of fresh colon tissue of the DIO mice (Fig. 5a), suggesting that ATP production exceeded ATP demand in the enterocytes of DIO mice. In the isolated mitochondria, the complex activities were tested by measuring mitochondrial OCR using the Seahorse technology. The complex I activity was increased, but the complex II and IV activities were decreased in the DIO mice (Fig. 5b, c). When the oxygen consumption was tested under the complex II substrate, the RCR of mitochondria was dramatically decreased in DIO mice, and partially restored by BBR (Fig. 5d). The combination of ATP elevation with complex I super-activation suggests that mitochondria were under a stress response in the DIO mice. The stress responses were corrected by BBR (Fig. 5a–d). These data suggest that mitochondrial stress may lead to the structural damage in DIO mice, which were all attenuated by BBR.

Fig. 5
Fig. 5

Protection of mitochondrial function in colon by BBR. a Total ATP level in the fresh colon tissue. b Complex activities of mitochondria. The complex activity was determined by the oxygen consumption rate (OCR) in response to the inhibitors in mitochondria isolated from the fresh colon tissue. The order of inhibitor injection was rotenone, succinate, antimycin A, and ascorbate plus N,N,N9,N9-tetramethyl-p-phenylenediamine (TMPD). c Mean value of maximal OCR in the complex assay. d Respiratory control rate (RCR). This was performed with complex II substrate succinate and complex I inhibitor rotenone. Data are presented as the mean ± SEM (n = 6). *P < 0.05 HFD versus NCD, #P < 0.05 HFD + BBR versus HFD

Induction of mitochondrial stress by fatty acids

To understand the cause of mitochondrial stress, we explored the effect of LCFAs on cell responses in a cellular model, in which the intestine epithelial cell line NCI-H716 was treated with palmitate (for palmitic acid). The study design was based on the elevation of LCFAs and reduction of GLP-1 secretion in the colon of DIO mice17. Palmitate level was increased in the large intestine by HFD (Fig. 6a). In response to palmitate treatment, ATP abundance was increased, and mitochondrial potential was decreased in the cellular model (Fig. 6b, c). Mitochondrial maximal respiration was decreased and cell apoptosis was elevated in the same condition (Fig. 6d, e). Cell necrosis was not observed in the model with PI staining of the dead cells (data not shown). When BBR was added into the cell culture, all of the changes were dramatically reduced or blocked (Fig. 6b, e). The data suggest that the mitochondrial stress was induced by palmitate and inhibited by BBR.

Fig. 6
Fig. 6

Regulation of mitochondrial stress and apoptosis in palmitate-treated cells by BBR. Palmitate was used to represent the long-chain fatty acid palmitic acid in the induction of mitochondrial stress responses in the intestine epithelial cell line NCI-H716. a Palmitate level in the large intestine. Palmitate was determined in the fecal samples. b ATP elevation in palmitate-treated cells. c Decline of mitochondrial potential in palmitate-treated cells. d Reduction in mitochondrial function in palmitate-treated cells. e Apoptosis in response to palmitate. Data are presented as the mean ± SEM (n = 3). *P < 0.05 PA versus control; #P < 0.05 PA + BBR versus PA

Regulation of SCFAs and gut microflora by BBR

SCFAs are produced in the large intestine by microflora-mediated fermentation of dietary fibers, and used by enterocytes as an energy source. Among SCFAs, butyrate (sodium salt of butyric acid) was reported to improve glucose metabolism18 and induce GLP-1 expression in L-cells19. A reduction in SCFAs may contribute to the mitochondrial stress in DIO mice. To test the possibility, six types of SCFAs (butyric acid, acetic acid, propionic acid, isobutyric acid, isovaleric acid, and valeric acid) were examined in the feces of mice. In the control lean mice, butyric, acetic and propionic acids were most abundant among the six SCFAs in the feces with concentrations between 140 and 260 µg/ml in the normal control mice (Fig. 7a–c), which were 3–5-fold higher than those of other three SCFAs of 20–35 µg/ml (Fig. 7d–f). In DIO mice, all of the six SCFAs were significantly reduced relative to the control mice (Fig. 7a–f). The most reduction was observed in butyric acid. The reduction was partially blocked by BBR in DIO mice, but remained significantly low especially in the three dominant SCFAs (butyric acid, acetic acid, and propionic acid). The data suggest that BBR may not have a significant effect on the regulation of SCFAs in DIO mice in this study. In the same condition, a dramatic improvement in L-cell function was observed with a little recovery in SCFAs, suggesting that SCFAs may not be an essential factor in the BBR activity.

Fig. 7
Fig. 7

Regulation of SCFAs and gut microflora by BBR. af The concentration of butyric acid, acetic acid, propionic acid, isobutyric acid, isovaleric acid, and valeric acid in feces of HFD mice after 8 weeks of BBR treatment. g Bacteria diversity in feces as indicated by ACE richness. h, i The abundance of Firmicutes and Bacteroidetes. j The Firmicutes/Bacteroidetes ratio. k–n The abundances of Clostridiales.g, Oscillospira, Parabacteroides, and Mogibacteriaceae.g. Data are presented as the mean ± SEM (n = 6). *P < 0.05 HFD versus NCD, #P < 0.05 HFD + BBR versus HFD

The gut microbiota was examined in the fecal samples to understand the basis of the SCFA alterations. The analysis was conducted using the 16s ribosomal RNA protocol14. An increase in microbiota diversity (richness and evenness) was observed with the Ace estimator in DIO mice (Fig. 7g). At the phylum level, Firmicutes and Bacteroidetes are the most abundant bacteria in the gut microflora. Firmicutes was increased, and Bacteroidetes was decreased in DIO mice (Fig. 7h, i). The ratio of Firmicutes to Bacteroidetes, a widely used marker of gut dysbiosis20, was increased by 10-folds in DIO mice (Fig. 7j). At the genus level, the relative abundance of Clostridiales.g and Oscillospira were increased by HFD (Fig. 7k, l). All of the alterations were improved in DIO mice by BBR (Fig. 7a–l). The relative abundance of Parabacteroides and Mogibacteriaceae.g were decreased in DIO mice and the decrease was reversed by BBR well above the normal level (Fig. 7m, n). The data suggest that BBR is able to correct dysbiosis in DIO mice.

Discussion

Protection of L-cell function represents a strategy in the promotion of GLP-1 secretion in favor of treatment of type 2 diabetes2,21,22. L-cell dysfunction has been reported in the DIO models for the GLP-1 reduction3,4,5. Although LCFAs have been reported to inhibit L-cell function through induction of endoplasmic reticulum stress or cell apoptosis23,24, the mitochondrial response in the L-cell dysfunction remains unknown. Our data suggest that the L-cell dysfunction is associated with mitochondrial stress responses. The stress was observed with alterations in structure and function of mitochondria. The structural alteration included cristae loss, membrane rupture, and mitochondrial swelling, which were observed together with an increase in ATP and a decrease in the respiration function. The stress was observed in the cellular model in response to the challenge by saturated LCFA (palmitic acid), suggesting a mechanism of L-cell dysfunction in the colon. The stress was inhibited by BBR in vitro and in vivo. Those data suggest that L-cell dysfunction may be a result of mitochondrial stress upon the challenge by LCFAs in the DIO model. The stress was associated with cell apoptosis (but not necrosis), which was consistent with the L-cell apoptosis reported in the DIO model and in GLP-1 secretion cell line3,23.

Our data suggest that the mitochondrial stress is characterized by ATP overproduction. Palmitic acid is known to induce cell apoptosis through induction of reactive oxygen species (ROS)25. However, the mechanism of ROS production was not identified in the study. Current study suggests that ATP elevation triggers the ROS production. The ATP elevation was observed in the colon tissues of DIO mice. The elevation is likely a result of over-supply of the LCFAs as suggested by the data of cellular model. The overproduction is supported by the activation of complex I in the colon tissue, which is a common mechanism in the control of ATP overproduction upon fuel over-loading in mitochondria26,27. The complex I is the major component in the production of ROS in mitochondria28. ROS is able to reduce ATP production through a decrease in the mitochondrial potential26,27. These data suggest that the complex I activation is a result of ATP overproduction in the colon. In addition, the ATP elevation may involve in a reduction in ATP hydrolysis following mitochondrial damage by ROS in some of the enterocytes. Mitochondria hydrolyze ATP to prevent a decrease in membrane potential in the physiological conditions29. When the ATP hydrolysis was inhibited by mitochondrial damage, ATP consumption is decreased to promote the ATP elevation. In vivo, infiltration of immune cells into the intestine may also contribute to the ATP elevation of DIO mice3.

Our data suggest that BBR may control the mitochondria stress by prevention of ATP overproduction, which is called “mitochondrial overheating” in the current study. Mitochondria produce superoxide in response to ATP overproduction, in which superoxide is able to open the mitochondrial permeability transition pore to reduce the mitochondrial potential to control ATP production27. In such a stress condition, ROS may abolish the mitochondrial potential through a damaging effect on the mitochondrial membrane. ATP overproduction is considered as a trigger of mitochondrial stress responses in the current study. The overproduction was downregulated by BBR in vitro and in vivo, which was coupled with prevention of the mitochondrial damage. The data suggest that BBR protected the mitochondria by suppression of ATP overproduction in DIO mice. The observation is consistent with the BBR activity in the suppression of oxidative phosphorylation in mitochondria7,8. These data suggest that BBR may protect L-cells by prevention of the mitochondrial overheating through a direct effect on mitochondria.

SCFAs may contribute to the BBR activity in the regulation of GLP-1 in vivo. BBR was reported to regulate the lipid metabolism through an impact on SCFAs30. In L-cells, SCFAs induce GLP-1 expression and secretion by stimulation of GPR43, which are supported by the effects of dietary fibers31,32. GPR43 gene knockout (FFAR2−/−) mice exhibited a reduction in GLP-1 secretion in vivo and in vivo16. In addition, SCFAs induce L-cell differentiation from progenitors21,33. In the current study, SCFAs were modestly up-regulated in DIO mice by BBR probably through an impact on dysbiosis. These studies suggested that SCFAs may contribute to the BBR effect on GLP-1 secretion. BBR was effective in the regulation of mitochondria in the cellular model in the absence SCFAs, which suggests that BBR may regulate GLP-1 expression independently.

In summary, the study demonstrates that mitochondria of colon enterocytes suffered a series of stress responses in the DIO mice for reduction in GLP-1 secretion. Oral administration of BBR inhibited the mitochondrial stress responses to restore the GLP-1 secretion in the mice. The mechanisms likely involve direct and indirect effect of BBR. The direct effect is down-regulation of the mitochondrial ATP production under the condition of LCFA challenge. The indirect includes correction of SCFAs and dysbiosis, which may contribute to the BBR activity in vivo.

Additional information

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

  1. 1.

    Patriti, A., Facchiano, E., Sanna, A., Gulla, N. & Donini, A. The enteroinsular axis and the recovery from type 2 diabetes after bariatric surgery. Obes. Surg. 14, 840–848 (2004).

  2. 2.

    Briere, D. A., Bueno, A. B., Gunn, E. J., Michael, M. D. & Sloop, K. W. Mechanisms to elevate endogenous GLP-1 beyond injectable GLP-1 analogs and metabolic surgery. Diabetes 67, 309–320 (2018).

  3. 3.

    Gniuli, D. et al. High-fat feeding stimulates endocrine, glucose-dependent insulinotropic polypeptide (GIP)-expressing cell hyperplasia in the duodenum of Wistar rats. Diabetologia 53, 2233–2240 (2010).

  4. 4.

    Aranias, T. et al. Lipid-rich diet enhances L-cell density in obese subjects and in mice through improved L-cell differentiation. J. Nutr. Sci. 4, e22 (2015).

  5. 5.

    Dusaulcy, R. et al. Functional and molecular adaptations of enteroendocrine L-cells in male obese mice are associated with preservation of pancreatic alpha-cell function and prevention of hyperglycemia. Endocrinology 157, 3832–3843 (2016).

  6. 6.

    Yin, J., Ye, J. & Jia, W. Effects and mechanisms of berberine in diabetes treatment. Acta Pharm. Sin. B 2, 327–334 (2012).

  7. 7.

    Yin, J., Gao, Z., Liu, D., Liu, Z. & Ye, J. Berberine improves glucose metabolism through induction of glycolysis. Am. J. Physiol. Endocrinol. Metab. 294, E148–E156 (2008).

  8. 8.

    Turner, N. et al. Berberine and its more biologically available derivative, dihydroberberine, inhibit mitochondrial respiratory complex I: a mechanism for the action of berberine to activate AMP-activated protein kinase and improve insulin action. Diabetes 57, 1414–1418 (2008).

  9. 9.

    Hou, W. L. et al. Inhibition of mitochondrial complex I improves glucose metabolism independently of AMPK activation. J. Cell Mol. Med. 22, 1316–1328 (2017).

  10. 10.

    Lu, S. S. et al. Berberine promotes glucagon-like peptide-1 (7-36) amide secretion in streptozotocin-induced diabetic rats. J. Endocrinol. 200, 159–165 (2009).

  11. 11.

    Yu, Y. et al. Modulation of glucagon-like peptide-1 release by berberine: in vivo and in vitro studies. Biochem. Pharmacol. 79, 1000–1006 (2010).

  12. 12.

    Gao, Z. et al. p65 inactivation in adipocytes and macrophages attenuates adipose inflammatory response in lean but not in obese mice. Am. J. Physiol. Endocrinol. Metab. 308, E496–E505 (2015).

  13. 13.

    Ke, B. et al. Inactivation of NF-kappaBp65 (RelA) in liver improved insulin sensitivity and inhibited cAMP/PKA pathway. Diabetes 64, E496–E505 (2015).

  14. 14.

    Eckburg, P. B. et al. Diversity of the human intestinal microbial flora. Science 308, 1635–1638 (2005).

  15. 15.

    Zhang, Y. et al. Induction of posttranslational modifications of mitochondrial proteins by ATP contributes to negative regulation of mitochondrial function. PLoS ONE 11, e0150454 (2016).

  16. 16.

    Tolhurst, G. et al. Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2. Diabetes 61, 364–371 (2012).

  17. 17.

    Muscelli, E. et al. Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients. Diabetes 57, 1340–1348 (2008).

  18. 18.

    Gao, Z. et al. Butyrate improves insulin sensitivity and increases energy expenditure in mice. Diabetes 58, 1509–1517 (2009).

  19. 19.

    Yadav, H., Lee, J. H., Lloyd, J., Walter, P. & Rane, S. G. Beneficial metabolic effects of a probiotic via butyrate-induced GLP-1 hormone secretion. J. Biol. Chem. 288, 25088–25097 (2013).

  20. 20.

    Ley, R. E. et al. Obesity alters gut microbial ecology. Proc. Natl Acad. Sci USA 102, 11070–11075 (2005).

  21. 21.

    Petersen, N. et al. Generation of L cells in mouse and human small intestine organoids. Diabetes 63, 410–420 (2014).

  22. 22.

    Petersen, N. et al. Targeting development of incretin-producing cells increases insulin secretion. J. Clin. Invest. 125, 379–385 (2015).

  23. 23.

    Hayashi, H. et al. Glucagon-like peptide-1 production in the GLUTag cell line is impaired by free fatty acids via endoplasmic reticulum stress. Metabolism 63, 800–811 (2014).

  24. 24.

    Thombare, K., Ntika, S., Wang, X. & Krizhanovskii, C. Long chain saturated and unsaturated fatty acids exert opposing effects on viability and function of GLP-1-producing cells: mechanisms of lipotoxicity. PLoS ONE 12, e0177605 (2017).

  25. 25.

    Egnatchik, R. A., Leamy, A. K., Noguchi, Y., Shiota, M. & Young, J. D. Palmitate-induced activation of mitochondrial metabolism promotes oxidative stress and apoptosis in H4IIEC3 rat hepatocytes. Metabolism 63, 283–295 (2014).

  26. 26.

    Wang, W. et al. Superoxide flashes in single mitochondria. Cell 134, 279–290 (2008).

  27. 27.

    Wang, X. et al. Mitochondrial flashes regulate ATP homeostasis in the heart. eLife 6, e23908 (2017).

  28. 28.

    Hirst, J. Mitochondrial complex I. Annu. Rev. Biochem. 82, 551–575 (2013).

  29. 29.

    Chen, W. W. et al. Inhibition of ATPIF1 ameliorates severe mitochondrial respiratory chain dysfunction in mammalian cells. Cell Rep. 7, 27–34 (2014).

  30. 30.

    Wang, Y. et al. Berberine-induced bioactive metabolites of the gut microbiota improve energy metabolism. Metabolism 70, 72–84 (2017).

  31. 31.

    Freeland, K. R., Wilson, C. & Wolever, T. M. Adaptation of colonic fermentation and glucagon-like peptide-1 secretion with increased wheat fibre intake for 1 year in hyperinsulinaemic human subjects. Br. J. Nutr. 103, 82–90 (2010).

  32. 32.

    Zhou, J. et al. Dietary resistant starch upregulates total GLP-1 and PYY in a sustained day-long manner through fermentation in rodents. Am. J. Physiol. Endocrinol. Metab. 295, E1160–E1166 (2008).

  33. 33.

    Kaji, I., Karaki, S., Tanaka, R. & Kuwahara, A. Density distribution of free fatty acid receptor 2 (FFA2)-expressing and GLP-1-producing enteroendocrine L cells in human and rat lower intestine, and increased cell numbers after ingestion of fructo-oligosaccharide. J. Mol. Histol. 42, 27–38 (2011).

Download references

Acknowledgements

The project was supported by the National Natural Science Foundation of China (81220108006) to WJ and JY. This study was also supported by the internal fund of the Shanghai Jiaotong University Affiliated Sixth People’s Hospital East to JY and YS.

Author information

Author notes

  1. These authors contributed equally: Yongning Sun, Chenxi Jin

Affiliations

  1. Department of Traditional Chinese Medicine, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, 200233, China

    • Yongning Sun
    •  & Jiamei Le
  2. Queen Mary School, Nanchang University, Nanchang City, Jiangxi Province, 330031, China

    • Chenxi Jin
  3. Central Laboratory, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital East, Shanghai, 201306, China

    • Xiaoying Zhang
    •  & Jianping Ye
  4. Diabetes Institute, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, 200233, China

    • Weiping Jia
    •  & Jianping Ye
  5. Antioxidant and Gene Regulation Laboratory, Pennington Biomedical Research Center, LSU, Baton Rouge, LA, 70808, USA

    • Jianping Ye

Authors

  1. Search for Yongning Sun in:

  2. Search for Chenxi Jin in:

  3. Search for Xiaoying Zhang in:

  4. Search for Weiping Jia in:

  5. Search for Jiamei Le in:

  6. Search for Jianping Ye in:

Contributions

YS, WJ and JY designed the study, wrote, and edited the manuscript. CJ, JL and XZ conducted the experiments, analyzed the data, prepared the figures, and drafted the manuscript. All authors have read and approved the manuscript.

Conflict of interest

The authors declare that they have no conflict of interest.

Corresponding authors

Correspondence to Jiamei Le or Jianping Ye.

Electronic supplementary material

About this article

Publication history

Received

Revised

Accepted

Published

DOI

https://doi.org/10.1038/s41387-018-0061-x